DPP4 and diabetes mellitus: DPP-4 inhibitors administered from the early stage of diabetes help to protect pancreatic β cells and normalize glucagon secretion control, combining reliable hypoglycemic action and safety, inhibiting the progression of diabetes and maintaining glycemic control, along with the potential for cardiovascular protection and anti-arteriosclerotic action [5-8].